Introduction to Treating Non Small

Sentence Examples

Discover more insights into Treating Non Small

Keywords frequently search together with Treating Non Small

Narrow sentence examples with built-in keyword filters

Treating Non Small sentence examples within cell lung cancer

cell lung cancer

The results indicate that [email protected] PCL-PEG nanoparticles can be further utilized for treating non-small-cell lung cancer as a promising therapeutic approach.

Co-Loading of Cisplatin and Methotrexate in Nanoparticle-Based PCL-PEG System Enhances Lung Cancer Chemotherapy Effects

cell lung cancer

Background Video-assisted thoracoscopic surgery lobectomy combined with lymphadenectomy is widely utilized worldwide for treating non-small cell lung cancer.

Long-term outcomes of video-assisted lobectomy in non-small cell lung cancer

More cell lung cancer sentences More Sentences

Treating Non Small sentence examples within epidermal growth factor

epidermal growth factor

The combination of Aidi injection (ADI) and epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) in treating non-small cell lung cancer (NSCLC) has been reported, but the effects of this therapy have not been systematically assessed.

Meta-Analysis of Aidi Injection and First-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Therapy in Treating Advanced Non-Small Cell Lung Cancer

epidermal growth factor

The optimal sequence for administration of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for treating non-small cell lung cancer (NSCLC) is still unclear.

Sequential Treatment of Afatinib and Osimertinib in Patients with Advanced Non-small Cell Lung Cancer Harboring EGFR Mutations: Results from a Real-world Study in South Korea

More epidermal growth factor sentences More Sentences

Treating Non Small sentence examples within growth factor receptor

growth factor receptor

Purpose Avitinib is the first third-generation epithelial growth factor receptor (EGFR) inhibitor independently developed in China and is mainly used for treating non-small cell lung cancer.

Effects of Avitinib on CYP450 Enzyme Activity in vitro and in vivo in Rats

More growth factor receptor sentences More Sentences

Learn more from Treating Non Small

More Treating Non Small sentence examples
10.1007/s10876-021-02101-9

The results indicate that [email protected] PCL-PEG nanoparticles can be further utilized for treating non-small-cell lung cancer as a promising therapeutic approach.

Co-Loading of Cisplatin and Methotrexate in Nanoparticle-Based PCL-PEG System Enhances Lung Cancer Chemotherapy Effects

More Treating Non Small sentence examples
10.1177/0218492321997380

Background Video-assisted thoracoscopic surgery lobectomy combined with lymphadenectomy is widely utilized worldwide for treating non-small cell lung cancer.

Long-term outcomes of video-assisted lobectomy in non-small cell lung cancer

More Treating Non Small sentence examples
10.2147/DDDT.S323186

Purpose Avitinib is the first third-generation epithelial growth factor receptor (EGFR) inhibitor independently developed in China and is mainly used for treating non-small cell lung cancer.

Effects of Avitinib on CYP450 Enzyme Activity in vitro and in vivo in Rats

More Treating Non Small sentence examples
10.1007/s10742-020-00234-4

We illustrate the methods using a case study evaluating the comparative effectiveness of robotic-assisted surgery, video-assisted thoracoscopic surgery and open thoracotomy for treating non-small cell lung cancer.

Estimation of causal effects of multiple treatments in healthcare database studies with rare outcomes

More Treating Non Small sentence examples
10.1016/j.adro.2021.100653

We sought to develop expert consensus guidance on the safe practice of treating non-small cell lung cancer with radiation therapy in the setting of prior thoracic irradiation.

An International Expert Survey on the Indications and Practice of Radical Thoracic Reirradiation for Non-Small Cell Lung Cancer

More Treating Non Small sentence examples
10.1016/j.phrs.2021.105574

Currently, conventional methods of treating non-small cell lung cancer (NSCLC) have many disadvantages.

Metabolomics and integrated network pharmacology analysis reveal Tricin as the active anti-cancer component of Weijing decoction by suppression of PRKCA and sphingolipid signaling.

More Treating Non Small sentence examples
10.1691/ph.2021.01018

Overall, we suggested a significant association between skin irAEs and the efficacy of PMB in treating non-small cell lung cancer.

Association between immune-related dermatologic adverse events and efficacy of pembrolizumab in non-small cell lung cancer patients.

More Treating Non Small sentence examples
10.1016/j.actbio.2021.05.018

It can be used for treating non-small cell lung cancer (NSCLC) patients with activating EGFR mutation and for patients who are resistant to first-generation EGFR TKIs due to T790M resistance mutation.

Nanoparticles for co-delivery of Osimertinib and Selumetinib to Overcome Osimertinib-acquired Resistance in Non-small Cell Lung Cancer.

More Treating Non Small sentence examples
10.1007/s11748-021-01692-4

Lobectomy is an established surgical procedure for treating non-small cell lung cancer; however, it significantly impacts postoperative cardiac function.

Selection of preoperative stress electrocardiography test for appropriate patients with non-small cell lung cancer

More Treating Non Small sentence examples
10.1101/2021.07.23.453506

Resistance to EGFR inhibitors (EGFRi) presents a major obstacle in treating non-small cell lung cancer (NSCLC).

Knowledge Graph-based Recommendation Framework Identifies Novel Drivers of Resistance in EGFR mutant Non-small Cell Lung Cancer

More Treating Non Small sentence examples
10.1177/2515690X211010733

The combination of Aidi injection (ADI) and epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) in treating non-small cell lung cancer (NSCLC) has been reported, but the effects of this therapy have not been systematically assessed.

Meta-Analysis of Aidi Injection and First-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Therapy in Treating Advanced Non-Small Cell Lung Cancer

More Treating Non Small sentence examples
10.3390/diagnostics11091695

Molecular evaluation of EGFR mutation is indispensable in treating non-small cell lung cancer (NSCLC).

Real-World Analysis of the EGFR Mutation Test in Tissue and Plasma Samples from Non-Small Cell Lung Cancer

More Treating Non Small sentence examples
10.21203/RS.3.RS-215079/V1

The optimal sequence for administration of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for treating non-small cell lung cancer (NSCLC) is still unclear.

Sequential Treatment of Afatinib and Osimertinib in Patients with Advanced Non-small Cell Lung Cancer Harboring EGFR Mutations: Results from a Real-world Study in South Korea

More Treating Non Small sentence examples
10.1038/s41598-021-99555-8

Cisplatin (CDDP) based chemotherapy is widely used as the first-line strategy in treating non-small cell lung cancer (NSCLC), especially lung squamous cell carcinoma (LUSC).

DLX6-AS1 activated by H3K4me1 enhanced secondary cisplatin resistance of lung squamous cell carcinoma through modulating miR-181a-5p/miR-382-5p/CELF1 axis.

More Treating Non Small sentence examples
10.14735/amko20193s6

PURPOSE The aim of this review is to summarise the current options for diagnosing and treating non-small cell lung cancer patients with uncommon EGFR mutations.

Uncommon EGFR Mutations in Non-Small Cell Lung Cancer and Their Impact on the Treatment.

More Treating Non Small sentence examples
10.3390/medicina55060294

Thus, the non-invasive nature and target specificity of DTX-NPs paves the way for its future use as a pulmonary delivery for treating non-small cell lung cancer (NSCLC).

Preparation, Optimization, and In Vivo Evaluation of Nanoparticle-Based Formulation for Pulmonary Delivery of Anticancer Drug

More Treating Non Small sentence examples
10.1016/B978-0-12-811785-9.00034-X

This chapter reviews the most recent data available regarding the role of immune checkpoint inhibitors in treating non-small cell lung cancer.

Immuno-Oncology in Lung Cancer: A Focus on Anti-PD-1 and Anti-CTLA-4 Therapy in NSCLC

More Treating Non Small sentence examples
10.18632/oncotarget.26622

Pemetrexed (MTA) is a folate antimetabolite used for treating non-small cell lung cancer.

FGF2-FGFR1 pathway activation together with thymidylate synthase upregulation is induced in pemetrexed-resistant lung cancer cells

More Treating Non Small sentence examples
10.1186/s12885-019-5686-1

BackgroundRadiation therapy is a standard form of treating non-small cell lung cancer, however, local recurrence is a major issue with this type of treatment.

Raman spectroscopy detects metabolic signatures of radiation response and hypoxic fluctuations in non-small cell lung cancer

More Treating Non Small sentence examples
10.1186/s12967-019-1803-9

BackgroundMET amplification is associated with acquired resistance to first-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) in treating non-small-cell lung cancer (NSCLC); however, the therapeutic strategy in these patients is undefined.

Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study

More Treating Non Small sentence examples
10.3389/fonc.2019.00004

Background: Nivolumab is an immune checkpoint inhibitor (ICI) that has shown efficacy for treating non-small cell lung cancer and has become a standard therapy for previously treated non-small cell lung cancer.

Pericardial Effusion With Tamponade in Lung Cancer Patients During Treatment With Nivolumab: A Report of Two Cases

More Treating Non Small sentence examples
10.1186/s12935-019-0941-8

ConclusionsThese results explored the mechanism of miR-21 promoted non-small cell lung cancer and might provide a novel therapeutic method in treating non-small cell lung cancer in clinic.

miR-21 promotes non-small cell lung cancer cells growth by regulating fatty acid metabolism

More Treating Non Small sentence examples
10.1016/j.taap.2019.114662

Although osimertinib, an EGFR tyrosine kinase inhibitor, has become the standard therapy for treating non-small cell lung cancer (NSCLC) patients with EGFR-activating mutation, upregulation of MCL-1 induces acquired resistance to osimertinib.

Degradation of MCL-1 by bufalin reverses acquired resistance to osimertinib in EGFR-mutant lung cancer.

More Treating Non Small sentence examples
10.1158/1538-7445.AM2019-1277

Osimertinib (AZD9291) is a FDA-approved EGFR inhibitor for treating non-small cell lung cancer (NSCLC) patients with activating EGFR mutations (first-line) or those who have become resistant to 1st generation EGFR inhibitors through the T790M mutation (second-line).

Abstract 1277: Honokiol, a natural product, overcomes acquired resistance of EGFR mutant NSCLC cells to the third generation EGFR inhibitor, osimertinib

More Treating Non Small sentence examples
10.1097/01.JAA.0000569792.99069.e6

Initially approved for use in metastatic melanoma, immunotherapy has found a significant place in treating non-small cell lung cancer (NSCLC).

Immunotherapy for non-small cell lung cancer.

More Treating Non Small sentence examples
10.2147/IJN.S193583

Herein, the effect of co-administered FMT and CpG on MΦ activation for treating non-small cell lung cancer (NSCLC) was explored.

Ferumoxytol and CpG oligodeoxynucleotide 2395 synergistically enhance antitumor activity of macrophages against NSCLC with EGFRL858R/T790M mutation

Learn more from Treating Non Small

Keywords related to Treating

Keywords related to Small

Treating Non Small
Encyclopedia

What is/are Treating Non Small?

Treating Non Small - The results indicate that [email protected] PCL-PEG nanoparticles can be further utilized for treating non-small-cell lung cancer as a promising therapeutic approach. [1] Background Video-assisted thoracoscopic surgery lobectomy combined with lymphadenectomy is widely utilized worldwide for treating non-small cell lung cancer. [2] Purpose Avitinib is the first third-generation epithelial growth factor receptor (EGFR) inhibitor independently developed in China and is mainly used for treating non-small cell lung cancer. [3] We illustrate the methods using a case study evaluating the comparative effectiveness of robotic-assisted surgery, video-assisted thoracoscopic surgery and open thoracotomy for treating non-small cell lung cancer. [4] We sought to develop expert consensus guidance on the safe practice of treating non-small cell lung cancer with radiation therapy in the setting of prior thoracic irradiation. [5] Currently, conventional methods of treating non-small cell lung cancer (NSCLC) have many disadvantages. [6] Overall, we suggested a significant association between skin irAEs and the efficacy of PMB in treating non-small cell lung cancer. [7] It can be used for treating non-small cell lung cancer (NSCLC) patients with activating EGFR mutation and for patients who are resistant to first-generation EGFR TKIs due to T790M resistance mutation. [8] Lobectomy is an established surgical procedure for treating non-small cell lung cancer; however, it significantly impacts postoperative cardiac function. [9] Resistance to EGFR inhibitors (EGFRi) presents a major obstacle in treating non-small cell lung cancer (NSCLC). [10] The combination of Aidi injection (ADI) and epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) in treating non-small cell lung cancer (NSCLC) has been reported, but the effects of this therapy have not been systematically assessed. [11] Molecular evaluation of EGFR mutation is indispensable in treating non-small cell lung cancer (NSCLC). [12] The optimal sequence for administration of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for treating non-small cell lung cancer (NSCLC) is still unclear. [13] Cisplatin (CDDP) based chemotherapy is widely used as the first-line strategy in treating non-small cell lung cancer (NSCLC), especially lung squamous cell carcinoma (LUSC). [14] PURPOSE The aim of this review is to summarise the current options for diagnosing and treating non-small cell lung cancer patients with uncommon EGFR mutations. [15] Thus, the non-invasive nature and target specificity of DTX-NPs paves the way for its future use as a pulmonary delivery for treating non-small cell lung cancer (NSCLC). [16] This chapter reviews the most recent data available regarding the role of immune checkpoint inhibitors in treating non-small cell lung cancer. [17] Pemetrexed (MTA) is a folate antimetabolite used for treating non-small cell lung cancer. [18] BackgroundRadiation therapy is a standard form of treating non-small cell lung cancer, however, local recurrence is a major issue with this type of treatment. [19] BackgroundMET amplification is associated with acquired resistance to first-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) in treating non-small-cell lung cancer (NSCLC); however, the therapeutic strategy in these patients is undefined. [20] Background: Nivolumab is an immune checkpoint inhibitor (ICI) that has shown efficacy for treating non-small cell lung cancer and has become a standard therapy for previously treated non-small cell lung cancer. [21] ConclusionsThese results explored the mechanism of miR-21 promoted non-small cell lung cancer and might provide a novel therapeutic method in treating non-small cell lung cancer in clinic. [22] Although osimertinib, an EGFR tyrosine kinase inhibitor, has become the standard therapy for treating non-small cell lung cancer (NSCLC) patients with EGFR-activating mutation, upregulation of MCL-1 induces acquired resistance to osimertinib. [23] Osimertinib (AZD9291) is a FDA-approved EGFR inhibitor for treating non-small cell lung cancer (NSCLC) patients with activating EGFR mutations (first-line) or those who have become resistant to 1st generation EGFR inhibitors through the T790M mutation (second-line). [24] Initially approved for use in metastatic melanoma, immunotherapy has found a significant place in treating non-small cell lung cancer (NSCLC). [25] Herein, the effect of co-administered FMT and CpG on MΦ activation for treating non-small cell lung cancer (NSCLC) was explored. [26]

cell lung cancer

The results indicate that [email protected] PCL-PEG nanoparticles can be further utilized for treating non-small-cell lung cancer as a promising therapeutic approach. [1] Background Video-assisted thoracoscopic surgery lobectomy combined with lymphadenectomy is widely utilized worldwide for treating non-small cell lung cancer. [2] We illustrate the methods using a case study evaluating the comparative effectiveness of robotic-assisted surgery, video-assisted thoracoscopic surgery and open thoracotomy for treating non-small cell lung cancer. [3] We sought to develop expert consensus guidance on the safe practice of treating non-small cell lung cancer with radiation therapy in the setting of prior thoracic irradiation. [4] Currently, conventional methods of treating non-small cell lung cancer (NSCLC) have many disadvantages. [5] Overall, we suggested a significant association between skin irAEs and the efficacy of PMB in treating non-small cell lung cancer. [6] It can be used for treating non-small cell lung cancer (NSCLC) patients with activating EGFR mutation and for patients who are resistant to first-generation EGFR TKIs due to T790M resistance mutation. [7] Lobectomy is an established surgical procedure for treating non-small cell lung cancer; however, it significantly impacts postoperative cardiac function. [8] Resistance to EGFR inhibitors (EGFRi) presents a major obstacle in treating non-small cell lung cancer (NSCLC). [9] Molecular evaluation of EGFR mutation is indispensable in treating non-small cell lung cancer (NSCLC). [10] Cisplatin (CDDP) based chemotherapy is widely used as the first-line strategy in treating non-small cell lung cancer (NSCLC), especially lung squamous cell carcinoma (LUSC). [11] PURPOSE The aim of this review is to summarise the current options for diagnosing and treating non-small cell lung cancer patients with uncommon EGFR mutations. [12] Thus, the non-invasive nature and target specificity of DTX-NPs paves the way for its future use as a pulmonary delivery for treating non-small cell lung cancer (NSCLC). [13] This chapter reviews the most recent data available regarding the role of immune checkpoint inhibitors in treating non-small cell lung cancer. [14] Pemetrexed (MTA) is a folate antimetabolite used for treating non-small cell lung cancer. [15] BackgroundRadiation therapy is a standard form of treating non-small cell lung cancer, however, local recurrence is a major issue with this type of treatment. [16] Background: Nivolumab is an immune checkpoint inhibitor (ICI) that has shown efficacy for treating non-small cell lung cancer and has become a standard therapy for previously treated non-small cell lung cancer. [17] ConclusionsThese results explored the mechanism of miR-21 promoted non-small cell lung cancer and might provide a novel therapeutic method in treating non-small cell lung cancer in clinic. [18] Although osimertinib, an EGFR tyrosine kinase inhibitor, has become the standard therapy for treating non-small cell lung cancer (NSCLC) patients with EGFR-activating mutation, upregulation of MCL-1 induces acquired resistance to osimertinib. [19] Osimertinib (AZD9291) is a FDA-approved EGFR inhibitor for treating non-small cell lung cancer (NSCLC) patients with activating EGFR mutations (first-line) or those who have become resistant to 1st generation EGFR inhibitors through the T790M mutation (second-line). [20] Initially approved for use in metastatic melanoma, immunotherapy has found a significant place in treating non-small cell lung cancer (NSCLC). [21] Herein, the effect of co-administered FMT and CpG on MΦ activation for treating non-small cell lung cancer (NSCLC) was explored. [22]

epidermal growth factor

The combination of Aidi injection (ADI) and epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) in treating non-small cell lung cancer (NSCLC) has been reported, but the effects of this therapy have not been systematically assessed. [1] The optimal sequence for administration of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for treating non-small cell lung cancer (NSCLC) is still unclear. [2] BackgroundMET amplification is associated with acquired resistance to first-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) in treating non-small-cell lung cancer (NSCLC); however, the therapeutic strategy in these patients is undefined. [3]

growth factor receptor

Purpose Avitinib is the first third-generation epithelial growth factor receptor (EGFR) inhibitor independently developed in China and is mainly used for treating non-small cell lung cancer. [1]